For over three decades, CEI has advocated health care reforms that put more power in the hands of consumers to choose their health providers, treatment protocols, and scope of insurance coverage. We have advocated reform of the Food and Drug Administration’s drug and device approval process to allow for greater flexibility and patient choice. And in 2013, CEI organized the court challenges to Obamacare’s exchange subsidies that concluded with the Supreme Court’s King v. Burwell decision.
Healthcare Issue Areas
Featured Posts
Blog
The free market case for AI chatbots in mental health care
Concerns that new technologies may cause negative psychosocial effects are part of a growing public conversation. Questions regarding the intersection between the digital world…
Blog
The fraud problem hidden in the subsidy debate
Last fall, critics argued that under the Republican budget plan, 22.4 million people would see their Obamacare subsidies reduced to prepandemic levels. As Jeremy…
News Release
FDA commissioner resignation opens opportunity for refocus on science over politics
After a somewhat tumultuous tenure, FDA commissioner Marty Makary is stepping down. While Dr. Makary made his mission to accelerate drug approval and bring…
Search Posts
Blog
The free market case for AI chatbots in mental health care
Concerns that new technologies may cause negative psychosocial effects are part of a growing public conversation. Questions regarding the intersection between the digital world…
Blog
The fraud problem hidden in the subsidy debate
Last fall, critics argued that under the Republican budget plan, 22.4 million people would see their Obamacare subsidies reduced to prepandemic levels. As Jeremy…
News Release
FDA commissioner resignation opens opportunity for refocus on science over politics
After a somewhat tumultuous tenure, FDA commissioner Marty Makary is stepping down. While Dr. Makary made his mission to accelerate drug approval and bring…
Blog
Don’t hinder biosimilar development
In its most recent legislative session, the Florida legislature considered precluding pharmacy benefit managers (PBMs) from holding an investment interest in biosimilar manufacturing.
Letters
CEI Joins TPA Coalition Letter on Reducing Barriers to Affordable Medications
Chair Scott, Ranking Member Gillibrand, and Members of the Committee:We, the undersigned organizations, representing millions of taxpayers and consumers across the country, urge you…
Blog
The unseen costs of banning PBM-owned pharmacies in Tennessee
Tennessee lawmakers recently passed the FAIR Rx Act, which would bar companies from owning pharmacies while also operating a pharmacy benefit manager (PBM)…